Omalizumab as add-on therapy to inhaled steroids for asthma
Tahar A H
Record ID 32004000643
English, French
Authors' objectives:
To summarize the available information on the use of omalizumab (Trade Name Xolair, developed jointly by Novartis Pharma AG, Genentech Inc., and Tanox, Inc.) in the management of moderate to severe allergic asthma that is inadequately controlled with inhaled corticosteroids.
Authors' recommendations:
In placebo-controlled trials, omalizumab reduces asthma exacerbations and the need for inhaled steroids in patients with moderate to severe asthma. The value of this drug to patients with refractory asthma has yet to be proven. Data are lacking on the efficacy of omalizumab compared to add-on therapies such as inhaled long-acting beta-2 agonists or anti-leukotriene agents. Further evaluation needs to be done on the pediatric population. Omalizumab's safety profile is of concern. Because of risk of anaphylaxis, this drug can only be administered by physicians. The high price of the drug as well as the means of administration could discourage its use.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anti-Asthmatic Agents
- Costs and Cost Analysis
- Asthma
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.